Search

everythinglearnresearchcommunity

for

Search:↓

CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.

Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.

The FDA approved a new Pfizer drug for hair loss in teens.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

The document's conclusion cannot be provided because the document is not available to parse.

GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

A new combination of tadalafil and finasteride improves drug performance and stability.

The drug combination significantly reduced epileptic drop attacks in patients.

The use of Diane-35 and its generics significantly decreased in the Netherlands.

Upadacitinib may effectively treat resistant lichen planopilaris.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Drug repurposing shows promise for treating many medical conditions.

CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.